Trial Profile
A Randomised, Single-blind, Placebo-controlled, Study to Assess the Safety and Tolerability of Single Escalating and Repeat, Inhaled Doses of PC945 in Healthy Subjects Combined With a Randomised, Single-blind, Placebo-controlled, Parallel Group to Assess the Safety and Tolerability of a Single Dose of Inhaled PC945 in Subjects With Mild Asthma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Mar 2021
Price :
$35
*
At a glance
- Drugs Opelconazole (Primary)
- Indications Aspergillosis
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Pulmocide
- 11 Mar 2021 Results presented in a Pulmocide media release.
- 11 Mar 2021 According to a Pulmocide media release, data from the study has been published in Pharmaceutical Research and Perspectives.
- 30 Apr 2018 Status changed from active, no longer recruiting to completed.